We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
- Authors
Viale, Giuseppe; Regan, Meredith M; Mastropasqua, Mauro G; Maffini, Fausto; Maiorano, Eugenio; Colleoni, Marco; Price, Karen N; Golouh, Rastko; Perin, Tiziana; Brown, R W; Kovács, Anikó; Pillay, Komala; Ohlschlegel, Christian; Gusterson, Barry A; Castiglione-Gertsch, Monica; Gelber, Richard D; Goldhirsch, Aron; Coates, Alan S; International Breast Cancer Study Group
- Abstract
Several small studies have reported that having a high percentage of breast tumor cells that express the proliferation antigen Ki-67 (ie, a high Ki-67 labeling index) predicts better response to neoadjuvant chemotherapy. However, the predictive value of a high Ki-67 labeling index for response to adjuvant chemotherapy is unclear. To investigate whether Ki-67 labeling index predicts response to adjuvant chemoendocrine therapy, we assessed Ki-67 expression in tumor tissue from 1924 (70%) of 2732 patients who were enrolled in two randomized International Breast Cancer Study Group trials of adjuvant chemoendocrine therapy vs endocrine therapy alone for node-negative breast cancer. A high Ki-67 labeling index was associated with other factors that predict poor prognosis. Among the 1521 patients with endocrine-responsive tumors, a high Ki-67 labeling index was associated with worse disease-free survival but the Ki-67 labeling index did not predict the relative efficacy of chemoendocrine therapy compared with endocrine therapy alone. Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies.
- Publication
Journal of the National Cancer Institute, 2008, Vol 100, Issue 3, p207
- ISSN
1460-2105
- Publication type
Journal Article
- DOI
10.1093/jnci/djm289